Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
Clinical trial NCT06656624 · RECRUITING
Trial details
- NCT number
- NCT06656624
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-13
- Primary completion
- 2025-12-31
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.